Market ExpansionManagement remains optimistic that this momentum will continue to steadily build across the estimated ~9M eligible patients, supported by broad payer coverage, prescriber engagement, and consumer campaigns.
Product AdoptionManagement noted the success it has seen in driving prescribing across patient segments, with 80% of its target ECPs prescribing Xdemvy across key patient segments, double the amount that had prescribed across segments on its fourth-quarter call.
Revenue GrowthTarsus reported Xdemvy revenue of $102.7 million in the second quarter, significantly beating both the estimate of $98.4 million and consensus of $96.3 million.